T. Rowe Price Associates
ACRS icon

T. Rowe Price Associates’s Aclaris Therapeutics ACRS Stock Holding History

T. Rowe Price Associates’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
221,599
+64,874
+41% +$289K ﹤0.01% 2254
2026
Q1 		$588K Buy
156,725
+16,558
+12% +$55.9K ﹤0.01% 2376
2025
Q4 		$422K Hold
140,167
– – ﹤0.01% 2471
2025
Q3 		$267K Sell
140,167
-26,200
-16% -$45.7K ﹤0.01% 2659
2025
Q2 		$237K Buy
166,367
+43,267
+35% +$58.5K ﹤0.01% 2633
2025
Q1 		$189K Hold
123,100
– – ﹤0.01% 2665
2024
Q4 		$306K Sell
123,100
-16,300
-12% -$40.6K ﹤0.01% 2500
2024
Q3 		$161K Hold
139,400
– – ﹤0.01% 2722
2024
Q2 		$154K Buy
139,400
+29,633
+27% +$34.8K ﹤0.01% 2661
2024
Q1 		$137K Buy
109,767
+1,252
+1% +$1.49K ﹤0.01% 2717
2023
Q4 		$114K Sell
108,515
-21,372
-16% -$65.2K ﹤0.01% 2693
2023
Q3 		$890K Buy
129,887
+80,907
+165% +$691K ﹤0.01% 1851
2023
Q2 		$508K Buy
48,980
+1,512
+3% +$13.7K ﹤0.01% 2116
2023
Q1 		$385K Buy
47,468
+756
+2% +$9.6K ﹤0.01% 2222
2022
Q4 		$736K Sell
46,712
-394
-0.8% -$6.34K ﹤0.01% 1943
2022
Q3 		$742K Buy
47,106
+9,077
+24% +$143K ﹤0.01% 1920
2022
Q2 		$531K Buy
38,029
+6,460
+20% +$90.5K ﹤0.01% 2201
2022
Q1 		$544K Sell
31,569
-774
-2% -$10.6K ﹤0.01% 2298
2021
Q4 		$470K Sell
32,343
-399
-1% -$6.04K ﹤0.01% 2410
2021
Q3 		$589K Sell
32,742
-9,235
-22% -$148K ﹤0.01% 2302
2021
Q2 		$737K Buy
41,977
+12,857
+44% +$292K ﹤0.01% 2201
2021
Q1 		$734K Buy
+29,120
New +$569K ﹤0.01% 2190
2019
Q4 		– Sell
-31,393
Closed -$34K – 2525
2019
Q3 		$34K Buy
31,393
+147
+0.5% +$209 ﹤0.01% 2499
2019
Q2 		$68K Buy
31,246
+20,800
+199% +$113K ﹤0.01% 2502
2019
Q1 		$63K Buy
+10,446
New +$69.2K ﹤0.01% 2491
2017
Q4 		– Sell
-340,343
Closed -$8.78M – 2562
2017
Q3 		$8.78M Sell
340,343
-67,400
-17% -$1.81M ﹤0.01% 1354
2017
Q2 		$11.1M Buy
407,743
+63,426
+18% +$1.72M ﹤0.01% 1305
2017
Q1 		$10.3M Buy
+344,317
New +$9.93M ﹤0.01% 1326

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

T. Rowe Price Associates's ACRS Position: Q2 2026 in Review

T. Rowe Price Associates increased its Aclaris Therapeutics (ACRS) stake by 41% in Q2 2026, buying an estimated $289K and bringing the position to 221,599 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2254.

T. Rowe Price Associates first reported a position in ACRS in Q1 2017 and has held it in 28 quarters since. The position peaked at $11.1M in Q2 2017. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • T. Rowe Price Associates held 221,599 shares of Aclaris Therapeutics worth $1.17M as of Q2 2026.
  • T. Rowe Price Associates bought 64,874 Aclaris Therapeutics shares in Q2 2026, an estimated $289K.
  • Aclaris Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2254 holding.
  • T. Rowe Price Associates first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Aclaris Therapeutics position peaked at $11.1M in Q2 2017.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.